A practical approach to risk assessment to prevent coronary artery disease and its complications

MacRae F. Linton, Sergio Fazio

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

The recent focus on emerging cardiovascular risk factors, such as C-reactive protein, homocysteine, and small, dense low-density lipoprotein (LDL), may give the false impression that the current approach to the assessment of cardiovascular disease risk fails to identify a large section of the high-risk population. On the contrary, the new guidelines of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) propose classifying an enormous number of individuals, including people with any form of atherosclerotic disease, diabetes, and a combination of major risk factors, into the category of high risk (>20% likelihood of a major coronary event or stroke in 10 years). Considering the widespread prevalence of the metabolic syndrome - a high-risk condition characterized by mild hypertension, mild dyslipidemia, hyperglycemia, and visceral obesity - we may be faced with the challenge of implementing aggressive risk reduction therapies in as much as 30% of the adult US population. From the point of view of risk assessment, a practical approach is to follow the NCEP guidelines (ie, place patients with diabetes and those with atherosclerotic complications in the highest risk category), apply the Framingham calculation to determine risk in people with common risk factors, and initiate early intervention in people who have familial hypercholesterolemia (LDL cholesterol >200 mg/dL) or a family history of early cardiovascular disease. The emerging risk factors may be useful for further stratifying risk in individuals with intermediate risk and the presence of risk factors not included in the Framingham calculation.

Original languageEnglish (US)
JournalAmerican Journal of Cardiology
Volume92
Issue number1 SUPPL.
DOIs
StatePublished - Jul 3 2003
Externally publishedYes

Fingerprint

Coronary Artery Disease
Cardiovascular Diseases
Guidelines
Hyperlipoproteinemia Type II
Abdominal Obesity
Homocysteine
Risk Reduction Behavior
Dyslipidemias
LDL Lipoproteins
Hyperglycemia
C-Reactive Protein
LDL Cholesterol
Population
Stroke
Cholesterol
Hypertension
Education
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A practical approach to risk assessment to prevent coronary artery disease and its complications. / Linton, MacRae F.; Fazio, Sergio.

In: American Journal of Cardiology, Vol. 92, No. 1 SUPPL., 03.07.2003.

Research output: Contribution to journalArticle

@article{6a8e58ad01a545fe9e1a177b52adf741,
title = "A practical approach to risk assessment to prevent coronary artery disease and its complications",
abstract = "The recent focus on emerging cardiovascular risk factors, such as C-reactive protein, homocysteine, and small, dense low-density lipoprotein (LDL), may give the false impression that the current approach to the assessment of cardiovascular disease risk fails to identify a large section of the high-risk population. On the contrary, the new guidelines of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) propose classifying an enormous number of individuals, including people with any form of atherosclerotic disease, diabetes, and a combination of major risk factors, into the category of high risk (>20{\%} likelihood of a major coronary event or stroke in 10 years). Considering the widespread prevalence of the metabolic syndrome - a high-risk condition characterized by mild hypertension, mild dyslipidemia, hyperglycemia, and visceral obesity - we may be faced with the challenge of implementing aggressive risk reduction therapies in as much as 30{\%} of the adult US population. From the point of view of risk assessment, a practical approach is to follow the NCEP guidelines (ie, place patients with diabetes and those with atherosclerotic complications in the highest risk category), apply the Framingham calculation to determine risk in people with common risk factors, and initiate early intervention in people who have familial hypercholesterolemia (LDL cholesterol >200 mg/dL) or a family history of early cardiovascular disease. The emerging risk factors may be useful for further stratifying risk in individuals with intermediate risk and the presence of risk factors not included in the Framingham calculation.",
author = "Linton, {MacRae F.} and Sergio Fazio",
year = "2003",
month = "7",
day = "3",
doi = "10.1016/S0002-9149(03)00505-8",
language = "English (US)",
volume = "92",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - A practical approach to risk assessment to prevent coronary artery disease and its complications

AU - Linton, MacRae F.

AU - Fazio, Sergio

PY - 2003/7/3

Y1 - 2003/7/3

N2 - The recent focus on emerging cardiovascular risk factors, such as C-reactive protein, homocysteine, and small, dense low-density lipoprotein (LDL), may give the false impression that the current approach to the assessment of cardiovascular disease risk fails to identify a large section of the high-risk population. On the contrary, the new guidelines of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) propose classifying an enormous number of individuals, including people with any form of atherosclerotic disease, diabetes, and a combination of major risk factors, into the category of high risk (>20% likelihood of a major coronary event or stroke in 10 years). Considering the widespread prevalence of the metabolic syndrome - a high-risk condition characterized by mild hypertension, mild dyslipidemia, hyperglycemia, and visceral obesity - we may be faced with the challenge of implementing aggressive risk reduction therapies in as much as 30% of the adult US population. From the point of view of risk assessment, a practical approach is to follow the NCEP guidelines (ie, place patients with diabetes and those with atherosclerotic complications in the highest risk category), apply the Framingham calculation to determine risk in people with common risk factors, and initiate early intervention in people who have familial hypercholesterolemia (LDL cholesterol >200 mg/dL) or a family history of early cardiovascular disease. The emerging risk factors may be useful for further stratifying risk in individuals with intermediate risk and the presence of risk factors not included in the Framingham calculation.

AB - The recent focus on emerging cardiovascular risk factors, such as C-reactive protein, homocysteine, and small, dense low-density lipoprotein (LDL), may give the false impression that the current approach to the assessment of cardiovascular disease risk fails to identify a large section of the high-risk population. On the contrary, the new guidelines of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) propose classifying an enormous number of individuals, including people with any form of atherosclerotic disease, diabetes, and a combination of major risk factors, into the category of high risk (>20% likelihood of a major coronary event or stroke in 10 years). Considering the widespread prevalence of the metabolic syndrome - a high-risk condition characterized by mild hypertension, mild dyslipidemia, hyperglycemia, and visceral obesity - we may be faced with the challenge of implementing aggressive risk reduction therapies in as much as 30% of the adult US population. From the point of view of risk assessment, a practical approach is to follow the NCEP guidelines (ie, place patients with diabetes and those with atherosclerotic complications in the highest risk category), apply the Framingham calculation to determine risk in people with common risk factors, and initiate early intervention in people who have familial hypercholesterolemia (LDL cholesterol >200 mg/dL) or a family history of early cardiovascular disease. The emerging risk factors may be useful for further stratifying risk in individuals with intermediate risk and the presence of risk factors not included in the Framingham calculation.

UR - http://www.scopus.com/inward/record.url?scp=0038303419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038303419&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(03)00505-8

DO - 10.1016/S0002-9149(03)00505-8

M3 - Article

C2 - 12867251

AN - SCOPUS:0038303419

VL - 92

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1 SUPPL.

ER -